Evaluation of the Truenat® chip-based real-time PCR platform for infectious disease diagnostics
Truenat assays showed reliable analytical performance, especially for COVID-19. While MTB detection remains more robust with Xpert Ultra in low-burden cases, Truenat provides a viable point-of-care alternative in resource-limited settings. For malaria and leptospirosis, broader clinical validation is needed before routine implementation in our service.
Authors
- Nair Hideko Muto (ORCID: https://orcid.org/0000-0001-8757-7029)
- Roberta Cardoso Petroni
- Rúbia Anita Ferraz Santana (ORCID: https://orcid.org/0000-0002-9488-1114)
- Fernanda de Mello Malta (ORCID: https://orcid.org/0000-0001-8887-5060)
- F. C. NUNES
- Marinês Dalla Valle Martino (ORCID: https://orcid.org/0000-0003-4801-7226)
- Ricardo Andreotti Siqueira (ORCID: https://orcid.org/0000-0003-0508-7398)
- João Renato Rebello Pinho
- Gabriela Rampazzo Cruz
- Ana Claudia Campana
- Cristóvão Luis Pitangueira Mangueira
- Roberta Miraglia
- Priscila de Meira Oliveria
- André Mario Doi
- Alice Friedenberg de Ulhoa Cintra
Institutions
- Brazilian Agricultural Research Corporation (BR)
- Hospital Israelita Albert Einstein (BR)
- Universidade Federal do Estado do Rio de Janeiro (BR)
Publication Details
- Journal
- Practical Laboratory Medicine
- Published
- 2026-02-05
- DOI
- https://doi.org/10.1016/j.plabm.2026.e00522
- Primary Topic
- Leptospirosis research and findings
- Type
- article
- Field-Weighted Citation Impact
- 0.00